39
Participants
Start Date
June 30, 2006
Primary Completion Date
November 30, 2008
Study Completion Date
April 30, 2009
MBP-426
Dose escalation starting at 6 mg/m2, IV (in the vein) on Day 1 of each 21-day cycle. Number of Cycles: Up to 6 cycles, until unacceptable toxicity, disease progression, or intercurrent illness requires treatment discontinuation. Patients may continue treatment beyond 6 cycles if the Investigator determines that additional treatment would provide further benefit for the patient as long as toxicity remains acceptable.
Institute for Drug Development, San Antonio
M.D. Anderson Cancer Center, Houston
Mebiopharm Co., Ltd
INDUSTRY